| Shire initiates search for new division president | Posted on 21/03/2007 in Pharmaceutical Company Restructures Shire has announced that it has begun its search for a replacement for David Pendergast, the president of the human genetic therapies business unit at the firm. Mr Pendergast is due to retire from this position at the end of the year.
The company reports that this search will be an external one, with the firm forecasting a smooth transition and shift of responsibilities to a "high calibre" candidate in the role.
Mr Pendergast has been president of this business division since 2005 when it was first acquired from Transkayrotic Therapies, with the unit currently employing 600 people worldwide, with this figure expected to increase by 270 over the next year with the planned building of new premises.
Matthew Emmens, chief executive officer of Shire, said: "David's contribution to Shire has been very significant.
"As the leader of our [human genetic therapies] business and as a member of the Shire management committee, he has consistently set stretch goals and ensured that the team has delivered on them - reflected in how the business is now expanding."
He added that the division was in a robust position and that in seeking a replacement for Mr Pendergast now, the company is confident it can appoint a candidate of a similarly high calibre to whom it can successfully transfer the responsibilities of the role.
Earlier this week, Shire announced that the waiting period under the Hart-Scott-Rodino antitrust legislation relating to the company's offer for New River Pharmaceuticals had expired.Other news stories from 21/03/2007
Read more in the Zenopa News Archive
How this news is generated
|  |
|
